Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell Metastatic
Status:
New, Open
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
See Screening Protocol LUNGMAP
NCT#05642572
